One of the two TAT arm of PIONEER AF-PCI (ASA + P2Y12 inhibitor + rivaroxaban 2.5mg twice daily) was excluded from the analysis as the rivaroxaban 2.5mg dose is not approved for prevention of thrombo-embolism in AF patients [2]. Here, P2RY12 is linked to atrial fibrillation.